Latest news with #HRI
Irish Examiner
2 hours ago
- Business
- Irish Examiner
John Sheridan the new general manager of Fairyhouse
John Sheridan has been appointed general manager of Fairyhouse Racecourse, HRI has confirmed. Sheridan joins from Vodafone Ireland, where he was Commercial Lead for the Consumer Prepay Division. He previously worked with betting firm Betdaq and for five years with Showjumping Ireland as Marketing Manager. Paul Dermody, CEO of HRI Racecourses, said: 'I am delighted to welcome John Sheridan to the role of General Manager at Fairyhouse Racecourse. John joins us at an exciting time for the racecourse team with interest in our flagship festivals increasing and an ever-growing list of race day and non-race day events demonstrating the popularity and appeal of the venue. "John will lead our engagement with the local community, commercial partners, tenants and industry stakeholders to drive Fairyhouse Racecourse on in a collaborative and sustainable way. 'John's commercial experience will bring so much to the role. One of his notable responsibilities at Betdaq was the management of the sponsorship of the Betdaq Champion Hurdle at the Punchestown Festival. John, a Kildare native, also enjoyed a spell as an amateur rider and he rode in a bumper at Fairyhouse in 2006.'
The Advertiser
2 days ago
- Health
- The Advertiser
Mini hearts to save cancer survivors from heart disease
Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts.
West Australian
2 days ago
- Health
- West Australian
Mini hearts to save cancer survivors from heart disease
Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts.
Perth Now
2 days ago
- Health
- Perth Now
Mini hearts to save cancer survivors from heart disease
Researcher Dr Clara Liu Chung Ming is seeking a therapy that protects cancer patients' hearts. (HANDOUT/Supplied by the Heart Research Institute) Researcher Dr Clara Liu Chung Ming is seeking a therapy that protects cancer patients' hearts. (HANDOUT/Supplied by the Heart Research Institute) Credit: AAP Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts.
The Irish Sun
01-08-2025
- Sport
- The Irish Sun
Ruby Walsh warns Thurles Racecourse ‘can't be lost forever' and urges Horse Racing Ireland to ‘stand up and be counted'
RUBY WALSH believes the impact on horse-racing from Thurles' closure will be "felt for some time". The privately-owned track in Tipperary - which hosted its first meeting in 1732 - has 2 Thurles Racecourse has closed with immediate effect Credit: Shauna Clinton/Sportsfile 2 Ruby Walsh has reacted to the closure Credit: David Fitzgerald/Sportsfile Riona Molony, whose family have owned the venue since the early 1900s, said rising costs were one of the reasons they had decided to pull the plug. Former jockey Ruby Walsh reacted to the shock news in his And he believes the impact on National Hunt Racing will be felt for some time. He wrote: "I doubt too many in the Irish racing world expected to wake up Friday morning after the drama of Thursday's Galway Hurdle to the news that Thurles race course was closing down." Read More on Ruby Walsh "This family-run enterprise has reached a crossroads, and the Molony ladies want a change. "Fair play to them, because the biggest calls are always the hardest to make, and like anyone in any walk of life, they have to do what is right for them." The 12-time Irish champion jockey warned that it won't be as simple as moving the fixtures set for Thurles to other race courses due to its adaptability to winter conditions. And he called for Horse Racing Ireland to "stand up and be counted" by facilitating a takeover of the track. Most read in Sport He continued: "The Molonys' statement does read like they are retiring from the business, but the course is still there, and perhaps another interested party can take over. "That might be something HRI can look into, but either way, Thurles on Thursday without Riona directing the show, Kate as her First Lieutenant, Trish and Helen running the coffee docks, and Anne-Marie making sure everyone else was busy, just won't be the same. Gordon Elliott and Noel Meade in surreal live RTE moment as they react to controversial Galway Hurdle ruling "It has a fabric, a core of local supporters, and an essential role to play in National Hunt racing. "It can't be lost forever, so the HRI board must stand up and be counted. "They are spending millions on the other side of the county on an all-weather track for a decreasing population of horses, so perhaps they could do something to help save a track that already exists, has the fixtures and the stock to fill the demand." Jockey The Cheltenham Festival-winning rider - who was O'Sullivan never recovered from a coma and In touching scenes at Cheltenham the following month, O'Sullivan's beloved horse Marine Nationale, who gave him his first Festival winner, 'HONOUR AND PRIVILEGE' In a statement, Riona Molony said: "It has been an honour and a privilege for our family to have run Thurles Racecourse, and I am officially announcing our retirement today. "We are very proud of the immense contribution our family has made to racing and we are most grateful to our extended racecourse family, our dedicated staff, generous sponsors, loyal patrons and the wider racing community for all your support. "Horseracing is part of the fabric of our family, and we have been very fortunate to have made so many great friends within the industry over the years. "My family and I look forward to going racing with you again, as spectators. "Since my beloved husband Pierce passed away in 2015, with the help of our four daughters Patricia, Helen, Ann Marie and Kate and our wonderful staff, we've managed to keep the show on the road and I know he would be very proud of us for that. "The girls all have their own families, careers and lives to live. "Ever increasing industry demands and the cost of doing business has also been a major factor. "We're going to enjoy this time together and relax now the decision is made and the news is out before we consider our options."
